Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent

Abstract

The present invention describes difluororthioacetamide oxazolidinones with a glycoloylpiperazine substituent as novel antibacterial agents, and antimicrobial combination therapies for combating infective diseases caused by gram-positive and gram-negative bacteria.

Description

FILED OF THE INVENTION

[0002] The present invention describes difluororthioacetamide oxazolidinones with a glycoloylpiperazine substituent as novel antibacterial agents, and antimicrobial combination therapies for combating infective diseases caused by gram-positive and gram-negative bacteria.

BACKGROUND OF THE INVENTION

[0003] The thioamide oxazolidinone antibacterial agents are a novel synthetic class of antimicrobials with broad activity against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, gram-negative aerobic bacteria such as H. influenzae and M. catarrahlis, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium avium.

[0004] As a chemical compound class, thioamide oxazolidinones generally are rapidly metabolized. It is known in the pharmaceutical filed that compounds with minimum metabolism are preferred to rapidly metabolized compounds for several reasons. It is easier to maintain therapeutic blood levels of slowly metabolized compounds (active ingredients) since they typically have lower clearance than rapidly metabolized compounds. Blood levels in humans are more predictable for slowly metabolized compounds since there is less effect from normal human variability in enzyme levels and activity. Metabolized compounds may also generate toxic metabolites, whereas non-metabolized compounds do not.

[0005] Accordingly, there is a demand to discover thioamide oxazolidinone antibacterial agents that possess minimum metabolism. Difluorothioacetamide oxazolidinones of the present invention have potent activity against gram-positive human and veterinary pathogens. In particular, it is unexpectedly discovered that these compounds have good stability in vivo and a very low metabolism rate.

INFORMATION DISCLOSURE

[0006] U.S. Pat. No. 6,342,513 discloses Oxazolidinone antibacterial agents having a thiocarbonyl functionality.

[0007] U.S. Pat. No. 6,281,210 discloses Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent.

[0008] U.S. Pat. No. 6,166,056 discloses phenyloxazolidinones having a C—C bond to 4-6 membered heterocyclic rings.

[0009] International publication WO 01/58885 discloses oxazolidinone thioamides with piperazine amide substituents.

SUMMARY OF THE INVENTION

[0010] The present invention provides a novel oxazolidinone compound of formula I 1

[0011] wherein X is N or CH;

[0012] R2 and R3 are independently H or F;

[0013] R1 is H, —CH2phenyl, or —C(═O)C1-4alkyl.

[0014] The present invention further provides a method for treating gram-positive bacterial infections which comprises administration to a mammal being treated a pharmaceutically effective amount of the compound of formula I, either individually, or in combination with other gram-positive antibiotics.

[0015] The present invention further provides a method for treating gram-positive and gram-negative bacterial infections which comprises administration to a mammal being treated a pharmaceutically effective amount of the compound of formula I in combination with at least one other gram-negative antibiotic.

[0016] The present invention further provides compositions for treating gram-positive bacterial infections wherein the compositions comprise a pharmaceutically effective amount of the compound of formula I and at least one other gram-positive antibiotic.

[0017] The present invention further provides compositions for treating gram-positive and gram-negative bacterial infections wherein the compositions comprise a pharmaceutically effective amount of the compound of formula I and at least one other gram-negative antibiotic.

[0018] The present invention further provides a compound of formula Ia as a intermediate useful for preparing a compound of formula I.

[0019] The present invention further provides methods of preparation of the compounds of formula I of the present invention.

[0020] The present invention further provides a use of the compound of formula I to prepare a medicament, for treating gram-positive and/or gram-negative bacterial infections.

DETAILED DESCRIPTION OF THE INVENTION

[0021] Definitions

[0022] The term “antibiotic” refers to an antibacterial agent other than the compound of the present invention.

[0023] Specifically, they refer to Amikacin, Gentamicin, Spectinomycin, Tobramycin, Imipenem, Meropenem, Cefadroxil, Cefazolin, Cephalexin, Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Loracarbef, Cefdinir, Cefixime, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftozoxime, Ceftriaxone, Cefepime, Azithromycin, Clarithromycin, Dirithromycin, Penicillin G, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Amoxicillin, Amoxicillin, Ampicillin, Mezlocillin, Piperacillin, Nalidixic Acid, Ciprofloxacin, Enoxacin, Lomefloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Sparfloxacin, Alatrofloxacin, Gatifloxacin, Moxifloxacin, Trimethoprim, Sulfisoxazole, Sulfamethoxazole, Doxycycline, Minocycline, Tetracycline, Aztreonam, Chloramphenicol, Clindamycin, Quinupristin, Fosfomycin, Metronidazole, Nitrofurantoin, Rifampin, Trimethoprim, and Vancomycin. All of them are known. They can be either obtained commercially or be prepared according to the references cited in PHYSICIANS' DESK REFERENCE, the 53rd Edition (1999) and the US FDA's Orange book.

[0024] The term “gram-positive antibiotic” refers to an antibacterial agent active against gram-positive bacterial organisms.

[0025] The term “gram-negative antibiotic” refers to an antibacterial agent active against gram-negative bacterial organisms.

[0026] For the purpose of the present invention, the carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Ci-j indicates a moiety of the integer “i” to the integer “j” carbon atoms, inclusive. Thus, the term “C1-4alkyl refers to alkyl of one to four carbon atoms, inclusive, or methyl, ethyl, propyl, and butyl, straight and branched forms thereof.

[0027] Specifically, R2 and R3 are H.

[0028] Specifically, R2 and R3 are F.

[0029] Specifically, R2 is H and R3 is F.

[0030] Specifically, R2 is F and R3 is H.

[0031] Specifically R1 is H.

[0032] Specifically R1 is —CH2phenyl.

[0033] Specifically R1 is —C(═O)C1-4alkyl.

[0034] Specifically, R1 is —C(═O)CH2phenyl

[0035] Specifically, X is N.

[0036] Specifically X is CH.

[0037] Examples of the present invention are:

[0038] (a) 2,2-difluoro-N-({(5S)-3-[3,5-difluoro-4-(4-glycoloyl-piperazine-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide,

[0039] (b) 2-{4-[4-((5S)-5-{[(2,2-difluoroethanethiolyl)-amino]methyl}-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl}-2-oxoethyl Acetate,

[0040] (c) 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(4-glycoloylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide,

[0041] (d) 2,2-difluoro-N-({(5S)-3-[4-glycoloylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-ethanethioamide,

[0042] (e) N-{[(5S)-3-(4-{4-[(benzyloxy)acetyl]piperazin-1-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-2,2-difluoroethanethioamide,

[0043] (f) 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(1-glycoloylpiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide, and

[0044] (g) 2,2-difluoro-N-({(5S)-3-[4-(1-glycoloylpiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide.

[0045] Description for the Preparations

[0046] Compounds of formula I of the present invention can be prepared as illustrated in Schemes I and II, wherein X, R1, R2 and R3 are as described previously or in claims. In Scheme I, R4 represents hydrogen, —C(═O)CH2OR1 or suitable amine protecting groups such as tert-butoxycarbonyl (Boc) and benzyloxycarbonyl (Cbz). The starting material, amines (II), can be prepared according to the procedure described in U.S. Pat. No. 6,342,523. Where R4 in the amine II is —C(═O)CH2OR1 or suitable amine protecting groups, they are allowed to react with an ester of difluoroethanethioic O-acid IV wherein R5 is C1-4 alkyl optionally substituted by one or two phenyl groups. Suitable solvents for this reaction include methanol, chloroform, methylene chloride or mixtures thereof at temperatures of about 10° C. to about 30° C. A tertiary amine base such as triethylamine can be used to facilitate this reaction, especially if a salt of the amine II is employed. As illustrated in Example 1 the Boc protecting group can be removed with acid catalysts such as trifluoroacetic acid in methylene chloride or 4N hydrogen chloride in dioxane at temperatures of about 0° C. to about 25° C. Removal of the Cbz group can be carried out with about 20% hydrogen bromide in acetic acid at temperatures about 0° C. to about 30° C. The remaining steps which lead from the resulting compounds wherein R4 is hydrogen to compounds of formula I are shown in Scheme II.

[0047] An alternative method for preparing compounds of formula I is illustrated in Scheme II. Condensation of a compound of structure V, wherein R6 is a protecting group such as Boc or Cbz, with difluoroacetic acid provides the difluoroacetamide VI. Reagents and conditions for this condensation include the use of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) with 4-(dimethylamino)pyridine (DMAP) in pyridine at temperature of about 0° C. to about 25° C. or EDC with 1-hydroxybenzotriazole hydrate (HOBT) and triethylamine in DMF at temperature of about 0° C. to about 25° C. The protecting groups R6 can then be removed to give compounds VII which can be converted to the thioamide VIII with Lawesson's Reagent. The reaction of VII with Lawesson's Reagent is facilitated by the use of 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone (DMPU) and can be carried out in solvents such as THF or dioxane at temperatures of about 20° C. to about 100° C. Condensation of the amines VIII with activated carboxylic acid derivatives will then give compounds of formula I. The reaction of VIII with acetoxyacetyl chloride and triethylamine in methylene chloride at temperature of about 0° C. to about 25° C., for example, can be used to prepare I where R1 is acetyl. Condensing agents such as EDC with the appropriate acids, as described above, can also be used for this reaction. Compounds where R1 is acetyl can be hydrolyzed to the corresponding compounds where R1 is hydrogen with aqueous potassium carbonate in methanol as illustrated in Example 3. 2

EXAMPLES

Example 1

Preparation of 2,2-difluoro-N-({(5S)-3-[3,5-difluoro-4-(4-glycoloyl-piperazine-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioaamide(6)

[0048] Step 1. Preparation of tert-butyl 4-[4-((5S)-5-{[(2,2-difluoroethanethioyl)amino]methyl}-2-oxo-1,3-oxazolidin-3-yl)-2,6-difluorophenyl]piperazine-1-carboxylate (2). 3

[0049] A stirred solution of 1 (prepared according to the procedure described in U.S. Pat. No. 6,342,523, example 29) (361 mg, 0.88 mmol) in 50% MeOH—CH2Cl2 (10 ml) is treated with O-(3,3-diphenylpropyl)difuoroethanethioate 3 (300 mg, 0.98 mmol), kept at ambient temperature (24° C.) for 30 min and concentrated. Flash chromatography of the residue on silica gel with 3% MeOH—CHCl3 gave 546 mg of 2, a colorless oil.

[0050] Method for Preparing O-(3,3-diphenylpropyl)difuoroethanethioate 3: 4

[0051] To a stirred solution of difluoroacetic acid (5.00 g, 52.1 mmol) and 3,3-diphenyl-1-propanol (11.4 ml, 57.3 mmol, 1.10 eq) in diethyl ether (100 ml) is added 4-dimethylaminopyridine (0.64 g, 5.21 mmol, 0.01 eq) followed by diisopropylcarbodiimide (6.56 g, 52.1 mmol, 1.0 eq). The mixture is stirred at room temperature overnight. The precipitate is removed by vacuum filtration and washed with ether and the filtrate concentrated in vacuo. The residue is filtered through a plug of silica gel using 5% ether/hexanes eluent and the filtrate collected and concentrated. The resulting compound (14.40 g, 46.64 mmol) in xylenes (150 ml) is added Lawesson's Reagent (24.1 g, 59.61 mmol). The reaction mixture is heated at reflux overnight and then cooled to room temperature. A precipitate formed which is removed by vacuum filtration and washed with ethyl acetate. The filtrate is passed through a plug of silica gel and eluted with 5% ether/hexanes and concentrated to give the title compound 3. 1H NMR (400 Mhz), CDCl3) δ 2.47, 4.07, 4.24, 5.82, 7.23.

[0052] Step 2. Preparation of N-{[(5S)-3-(3,5-difluoro-4-piperazin-1-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-2,2-difluoroethanethioamide trifluoroacetate (4). 5

[0053] A stirred mixture of 2 (576 mg) and trifluoroacetic acid (5 ml) is kept under nitrogen, at ambient temperature (24° C.) for 30 min, diluted with methylene chloride and concentrated to give the title compound (4) as oil.

[0054] Step 3. Preparation of 2-{4-[4-((5S)-5-{[(2,2-difluoroethanethioyl)amino]methyl}-2-oxo-1,3-oxazolidin-3-yl)-2,6-difluorophenyl]piperazin-1-yl}-2-oxoethyl acetate (5). 6

[0055] A stirred solution of 4, the product from Step 2, and triethylamine (268 μL, 1.92 mmol) in CH2Cl2 (10 ml) is cooled, under nitrogen, to 0° C. and treated, dropwise with acetoxyacetyl chloride (103 μL, 0.96 mmol). It is kept at 0° C. for 30 min, diluted with CH2Cl2 and washed with saturated NaHCO3 and brine. The organic solution is dried (Na2SO4) and concentrated to give 679 mg of the title compound (5) as oil.

[0056] Step 4. Preparation of 2,2-difluoro-N-({(5S)-3-[3,5-difluoro-4-(4-glycoloyl-piperazine-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethio amide(6). 7

[0057] A stirred solution of 5 (679 mg) in MeOH (10 ml) is cooled to 0° C., under nitrogen and treated with 10% aqueous K2CO3 (1 ml). It is kept at ambient temperature (24° C.) for 30 min, treated with additional 10% K2CO3 (1 ml), kept for 60 min, treated with additional 10% K2CO3 (0.5 ml) and stirred for 30 min. The resulting solution is mixed with saturated NaHCO3 and extracted with 5% MeOH—CH2Cl2. The extract is dried and concentrated. Flash chromatography of the residue on silica gel with 25-35% EtOAc-1% MeOH—CHCl3 followed by 5% MeOH—CHCl3 and crystallization of the product from EtOAc-heptane gave 163 mg of the title compound (6).

[0058] Physical data: mp 91-93° C. (dec).

[0059] MS (ESI+) m/z 465 (M+H+), 487 (M+Na+); MS (ESI−) m/z 463 (M−H).

[0060] HRMS calcd for C18H21F4N4O4S (M+H+) 465.1219, found 465.1221.

[0061] Anal calcd for C18H20F4N4O4S: C, 46.55; H, 4.34; N, 12.06. Found: C, 46.94; H, 4.57; N, 11.47.

Example 2

Preparation of 2-{4-[4-((5S)-5-{[(2,2-difluoroethanethiolyl)amino]methyl}-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl}-2-oxoethyl Acetate(11)

[0062] Step 1. Preparation of benzyl 4-[4-((5S)-5-{[(difluoroacetyl)amino]methyl}-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazine-1-carboxylate (8). 8

[0063] An ice cold stirred mixture of 7 (prepared according to the procedure described in U.S. Pat. No. 6,342,523, example 141) (2.00 g, 4.67 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 1.97 g, 10.3 mmol), 1-hydroxybenzotriazole hydrate (HOBT, 694 mg, 5.14 mmol), triethylamine (3.0 ml), difluoroacetic acid (0.38 ml, 6.07 mmol) and DMF (50 ml) is warmed to ambient temperature (24° C.), kept for 4 days and concentrated in vacuo. A mixture of the residue and CH2Cl2 is washed with water, dried (MgSO4) and concentrated. Recrystallization of the residue from CH2Cl2-MeOH-hexane gave 1.47 g of the title compound (8). mp 147° C.; MS (EI) m/z 506 (M+).

[0064] Step 2. Preparation of 2,2-difluoro-N-{[(5S)-3-(3-fluoro-4-piperazin-1-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide (9). 9

[0065] A mixture of 8 (1.40 g, 2.76 mmol), concentrated hydrochloric acid (0.690 mL, 8.28 mmol), 10% palladium-on-carbon catalyst (350 mg) and 95% EtOH (48 mL), is hydrogenated at an initial pressure of 40 psi for 18 hours and filtered through celite. The solid is washed with 40% H2O-EtOH and the filtrate is concentrated to remove EtOH. The resulting solution is neutralized with saturated NaHCO3 and extracted with 15% MeOH—CH2Cl2. The extract is dried (MgSO4) and concentrated to give 892 mg of the title compound (9) as a white foam: MS (EI) m/z 372 (M+).

[0066] Step 3. Preparation of 2,2-difluoro-N-{[(5S)-3-(3-fluoro-4-piperazin-1-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}ethanethioamide (10). 10

[0067] A stirred mixture of 9 (846 mg, 2.27 mmol), Lawesson's Reagent (1.84 g, 4.54 mmol), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU, 1.1 mL, 9.08 mmol) and THF (16 ml) is kept at ambient temperature (24° C.) for 18 hours and concentrated in vacuo. A mixture of the residue in 3N HCl is washed with CH2Cl2; the aqueous layer is then neutralized with solid NaHCO3 and extracted with CH2Cl2. The extract is dried and concentrated to give 574 mg of the title compounds (10). MS (EI) m/z 388.1 (M+), 346.0, 344.1, 302.1, 208.1.

[0068] Step 4. Preparation of 2-{4-[4-((5S)-5-{[(2,2-Difluoroethanethiolyl)amino]methyl}-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl}-2-oxoethyl Acetate (11). 11

[0069] An ice cold stirred mixture of 10 (450 mg, 1.16 mmol), HOBT (172 mg, 1.28 mmol), acetoxyacetic acid (178 mg, 1.51 mmol) and DMF (9.2 ml) is treated with EDC (489 mg, 2.55 mmol), warmed slowly to ambient temperature (24° C.) and kept at this temperature for 2 days. It is then concentrated in vacuo and the residue is chromatographed on silica gel with 2-2.5% MeOH—CH2Cl2 to give 322 mg of the title compound (11) MS (EI) m/z 488.1 (M+), 444.1, 343.1, 308.1, 266.1.

EXAMPLE 3

Preparation of 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(4-glycoloyl piperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide(12)

[0070] 12

[0071] An ice cold, stirred solution of 11 (300 mg, 0.614 mmol) in MeOH (20 ml) is treated with 10% aqueous K2CO3 (1.4 ml), kept for 1 hour and treated with 1M KHSO4 (5 ml) and water (20 ml). It is extracted with CH2Cl2 and the extract is dried (MgSO4) and concentrated to give 280 mg of 12. A sample is chromatographed on silica gel with 5% MeOH—CH2Cl2 and the title compound (12) is crystallized from Et2O-hexane and dried at 70° C. for 18 hours.

[0072] Physical data: MS (EI) m/z 446.0 (M+), 402.0, 266.1.

[0073] Anal calcd for C18H21F3N4O4S; C, 48.43; H, 4.74; N, 12.55. Found: C, 48.19; H, 4.75; N, 12.47.

Example 4

Preparation of 2,2-difluoro-N-({(5S)-3-[4-glycoloylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioaamide(14)

[0074] 13

[0075] A stirred, ice cold suspension of 13 (prepared according to the procedure described in U.S. Pat. No. 6,342,523, Example 65) (504.4 mg, 1.36 mmol) in CH2Cl2 (5 ml), under nitrogen is treated with triethylamine (0.29 ml, 2.08 mmol) and then with a solution of 3 (489 mg, 1.60 mmol) in CH2Cl2 (1 ml). It is kept in the ice bath for 15 min and at ambient temperature (24° C.) for 30 min and then concentrated in vacuo. Chromatography of the residue on silica gel with 50% EtOAc-CH2Cl2 followed by mixtures of MeOH—CH2Cl2 containing 2.5-5% MeOH and crystallization of the product from CH2Cl2-EtOAc-hexane gave 357 mg of the title compound (14).

[0076] Physical data: mp 158-159° C.

[0077] HRMS calcd for C18H23F2N4O4S (M++) 429.1408, found 429.1411.

[0078] Anal. Calcd for C18H22F2N4O4S: C, 50.46; H, 5.18; N, 13.08; S, 7.48. Found: C, 50.22; H, 5.19; N, 12.92; S, 7.40.

Example 5

Preparation of N-{[(5S)-3-(4-{4-[(benzyloxy)acetyl]piperazin-1-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-2,2-difluoroethanethioamide(16)

[0079] 14

[0080] As described for the preparation of 14, the reaction of 15 ((prepared according to the procedure described in U.S. Pat. No. 6,342,523) with 3 and triethylamine in CH2Cl2 gave the title compound (16) which is purified by silica gel chromatography with 1-2% MeOH—CH2Cl2 and crystallization from acetone-hexane.

[0081] Physical data: mp 166-168° C.

[0082] MS (ESI+) m/z 519.1 (M+H+), 541.3 (M+Na+); MS (ESI−) m/z 517.1 (M−H).

[0083] HRMS calcd for C25H29F2N4O4S (M+H+) 519.1877, found 519.1882.

[0084] Anal calcd for C25H28F2N4O4S: C, 57.90; H, 5.44; N, 10.80. Found: C, 58.73; H, 5.71; N, 10.62.

Example 6

Preparation of (5S)-5-{[(2,2-difluoro-1-sulfinylethyl)amino]methyl}-3-[3-fluoro-4-(4-glycoloylpiperazin-1-yl)phenyl]-1,3-oxazolidin-2-one(17)

[0085] 15

[0086] A stirred, ice cold mixture of 12 (0.42 g, 0.94 mmol) and MeOH (5 ml), under nitrogen, is treated, dropwise with a mixture of selenium dioxide (0.105 g, 0.946 mmol) and 30% hydrogen peroxide (0.12 ml) in water (1.5 ml), kept in the ice bath for 35 min and diluted with water (6 ml). It is extracted with CH2Cl2; the extract is washed with water and brine, dried (Na2SO4) and concentrated in vacuo without heating. Chromatography of the residue on silica gel with 50-100% acetone-CH2Cl2 and crystallization of the product from acetone gave 0.09 g of the title compound (18).

[0087] Physical data: mp 103-104° C.

[0088] HRMS calcd for C18H22F3N4O5S (M+H+) 463.1263, found 463.1269.

[0089] Anal calcd for C18H21F3N4O5S. (CH3)2CO: C, 48.46; H, 5.23; N, 10.76. Found: C, 48.55; H, 5.30; N, 10.73.

Example 7

Pyridinium 2-{4-[4-((5S)-5-{[(2,2-Difluoroethanethiolyl)amino]-methyl}-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl}-2-oxoethyl sulfate (18)

[0090] 16

[0091] A stirred mixture of 12 (0.31 g, 0.695 mmol) and DMF (3 ml), under nitrogen, was treated, portionwise during 5 minutes, with pyridine-sulfur trioxide complex (0.384 g, 2.76 mmol) and the resulting solution was kept at ambient temperature for 50 min and then concentrated in vacuo. The residue was cooled in an ice bath and treated during 5 min with a solution of NaHCO3 (0.23 g, 2.7 mmol) in water (7 ml). The resulting white solid was collected by filtration and dried in vacuo to give 0.36 g of 17: mp 205-206° C. (dec); MS (ESI−) m/z 524.95 (M−H); HRMS calcd for C18H20F3N4O7S2+H2 527.0881, found 527.0873; IR (DRIFT) 3233, 3300-2500 (broad) 1751, 1662, 1645 cm−1. Anal. Calcd for C23H26F3N5O7S2: C, 45.61H, 4.33; N, 11.56, S, 10.59. Found: C, 44.79; H, 4.43; N, 11.44; S, 10.64.

Example 8

Preparation of 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(1-glycoloylpiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (27). Step 1

[0092] Preparation of (5S)-5-(aminomethyl)-3-(3-fluoro-4-piperidin-4-ylphenyl)-1,3-oxazolidin-2-one (20). 17

[0093] A stirred mixture of 19 (Prepared according to the procedure described in U.S. Pat. No. 6,342,523) (3.70 g, 9.40 mmol) in 6N HCl (94 ml) is warmed at 75-80° C. for 7 hours, cooled in an ice bath, adjusted to pH 13 with solid NaOH, saturated with NaCl and extracted with CH2Cl2. The extract is dried (Na2SO4) and concentrated in vacuo. Chromatography of the residue on silica gel with 5-15% MeOH-1% NH4OHCH2Cl2 gave 1.78 g of the title compound (20).

[0094] Step 2. Preparation of (5S)-5-[(benzylideneamino)methyl]-3-(3-fluoro-4-piperidin-4-ylphenyl)-1,3-oxazolidin-2-one (21). 18

[0095] A stirred mixture of 63 (1.77 g, 6.03 mmol) and benzaldehyde (612 μL) in toluene (120 ml) is refluxed, under nitrogen for 5 hours, cooled to ambient temperature (24° C.) and treated with Na2SO4. It is stirred for 18 hours, filtered, and concentrated in vacuo to give the title compound (21).

[0096] Step 3. Preparation of (5S)-5-[(benzylideneamino)methyl]-3-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}-3-fluorophenyl)-1,3-oxazolidin-2-one (22). 19

[0097] An ice cold, stirred solution of the product (21) from Step 2 in CH2Cl2 (30 ml) under nitrogen is treated with triethylanmine (1.26 ml, 9.04 mmol) and benzyloxyacetyl chloride (1.00 mL, 6.33 mmol), kept in the ice bath for 2 hours and diluted with CH2Cl2. It is washed with water and brine, dried (Na2SO4) and concentrated in vacuo to give the title compound (22). MS (ESI−) m/z 528 (M−H).

[0098] Step 4. Preparation of (5S)-5-(aminomethyl)-3-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}-3-fluorophenyl)-1,3-oxazolidin-2-one (23) 20

[0099] A mixture of the product (22) from Step 3, 10% palladium-on-carbon catalyst (1.28 g) and MeOH (60 ml) is hydrogenated at an initial pressure of 20-40 psi for 42 hours and filtered through celite. The filtrate is concentrated in vacuo and the residue is chromatographed on silica gel with 2.5-15% MeOH—CH2Cl2 to give the title compound (23). HRMS calcd for C24H29FN3O4 (M+H+) 442.2142, found 442.2144.

[0100] Step 5. Preparation of tert-butyl [(5S)-3-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl]methylcarbamate (24). 21

[0101] A stirred solution of 23 (340 mg, 0.793 mmol) in CH2Cl2 (8 ml), under nitrogen is treated with di-tert-butyl dicarbonate (190 mg, 0.872 mmol) and kept at ambient temperature for 2 hours. It is then diluted with CH2Cl2, washed with water, saturated NaHCO3 and brine, dried (Na2SO4) and concentrated in vacuo. Chromatography of the residue on silica gel with 1-2% MeOH—CH2Cl2 gave the title compound (24). MS (ESI+) m/z 542 (M+H+), 564 (M+Na+).

[0102] Step 6. Preparation of tert-butyl {(5S)-3-[3-fluoro-4-(1-glycoloylpiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methylcarbamate (25). 22

[0103] A mixture of 24 (365 mg, 0.674 mmol) and 10% palladium-on-carbon catalyst (144 mg) in MeOH (13 ml) is hydrogenated at an initial pressure of 40 psi for 2.5 hours and filtered through celite. The filtrate is concentrated in vacuo to give the title compound (25). MS (ESI+) m/z 452 (M+H+), 474 (M+Na+).

[0104] Step 7. Preparation of (5S)-5-(aminomethyl)-3-[3-fluoro-4-(1-glycoloylpiperidin-4-yl)phenyl]-1,3-oxazolidin-2-one hydrochloride (26). 23

[0105] An ice cold, stirred solution of 25 (280 mg, 0.620 mmol) in MeOH (3 ml) is treated with 4M HCl in dioxane (6 ml), kept in the ice bath for 1 hour and concentrated in vacuo to give the title compound (26). MS (ESI+) m/z 352 (M+H+), MS (ESI−) m/z 386 (M+Cl).

[0106] Step 8. Preparation of 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(1-glycoloylpiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide(27). 24

[0107] As described in the step 2, Example 1, a mixture of 26 and triethylamine in CH2Cl2 is allowed to react with 3 to give the title compound (27) which is purified by silica gel chromatography with 1-2% MeOH—CH2Cl2 and crystallization from EtOAc-hexane.

[0108] Physical data: mp 151-152° C. MS (ESI+) m/z 446 (M+H+), 468 (M+Na+).

[0109] MS (ESI−) m/z 444 (M−H). Anal calcd for C19H22F3N3O4S: C, 51.23; H, 4.98; N, 9.43. Found: C, 51.23; H, 5.05; N, 9.35.

Example 9

Preparation of 2,2-difluoro-N-({(5S)-3-[4-(1-glycoloylpiperidine-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide(29)

[0110] 25

[0111] Following the procedure described in Example 7 but using a non-subsitituted phenyl starting material, compound 28 is prepared. Condensation of 28 with 3 and triethylamine in CH2Cl2 gave the title compound (29) which is purified by silica gel chromatography with 1-4% MeOH—CH2Cl2 and recrystallization from EtOAc-hexane.

[0112] Physical data: mp 140-141° C.

[0113] BRMS calcd for C19H24F2N3O4S (M+H+) 428.1455, found 428.1426.

[0114] Anal. calcd for C19H23F2N3O4S: C, 53.39; H, 5.42; N, 9.83. Found: C, 53.34; H, 5.40; N, 9.77.

[0115] Pharmaceutical Salts

[0116] The compound of formula I may be used in its native form or as a salt. In cases where forming a stable nontoxic salt is desired, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ketoglutarate, and glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, hydrobromide, sulfate, nitrate, bicarbonate, and carbonate salts. Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a compound of the present invention with a suitable acid affording a physiologically acceptable anion.

[0117] Doses for Individual/Combination Therapy

[0118] In combating the infective diseases caused by gram-positive organisms, the compound of the formula I can be used either individually, or in combination with other antibiotics that are active against gram-positive organisms. Some of the gram-positive antibiotics may also have activity against gram-negative organisms.

[0119] Examples of such gram-positive antibiotics are listed in Table 1.

TABLE 1
Gram-Positive Antibiotics That May Be Used
In a Combination Therapy With The Compound of Formula I
AGENTS	LO DOSE	HI DOSE	STD DOSE
AMINOGLYCOSIDES
Amikacin					15	mg/kg/day
Gentamicin	1	mg/kg/day	5	mg/kg/day
	.5	mg/kg	2.5	mg/kg
Spectinomycin			40	mg/kg
Tobramycin	1	mg/kg/day	5	mg/kg/day
	.5	mg/kg/day	5	mg/kg/day
PENEMS
Imipenem/cilastatin	62.5	mg	1	g
	6.25	mg/kg	25	mg/kg
Meropenem					40	mg/kg
	.5	mg/kg	2.5	mg/kg
1ST GEN CEPHS
Cefadroxil	.25	g/day	2	g/day
					30	mg/kg/day
Cefazolin	62.5	mg	1.5	g
	6.25	mg/kg/day	100	mg/kg/day
Cephalexin	62.5	mg	500	mg
	6.25	mg/kg/day	50	mg/kg/day
2ND GEN CEPHS
Cefaclor	62.5	mg	500	mg
	5	mg/kg/day	40	mg/kg/day
Cefotetan	0.125	g	3	g
	10	mg/kg/day	80	mg/kg/day
Cefoxitin	.25	g	3	g
	20	mg/kg/day	160	mg/kg/day
Cefprozil	62.5	mg	500	mg
	1.87	mg/kg/dose	15	mg/kg/dose
Cefuroxime	187.5	mg	3	g
	31.25	mg	500	mg
	12.5	mg/kg/day	150	mg/kg/day
	31.25	mg/kg/day	500	mg/kg/day
Loracarbef	50	mg	400	mg
	3.75	mg/kg/day	500	mg/kg/day
3RD GEN CEPHS
Cefdinir	75	mg			600	mg
Cefixime	50	mg			400	mg
Cefoperazone	.5	g/day	12	g/day
	25	mg/kg/day	150	mg/kg/day
Cefotaxime	.25	g	2	g
	12.5	mg/kg/dose	300	mg/kg/day
Cefpodoxime	25	mg	400	mg	10	mg/kg/day
Ceftazidime	62.5	mg	2	g q8
	25	mg/kg/day	150	mg/kg/day
Ceftibuten	2.25	mg/kg	400	mg	400	mg
Ceftozoxime	.25	g	4	g
	12.5	mg/kg/day	200	mg/kg/day
Ceftriaxone	31.25	mg	2	g
	12.5	mg/kg/day	100	mg/kg/day
4TH GEN CEPHS
Cefepime	0.125	g	2	g
	12.5	mg/kg	50	mg/kg q8
MACROLIDES
Azithromycm	62.5	mg	500	mg
	62.5	mg	500	mg
Clarithromycin	62.5	mg	500	mg	7.5	mg/kg/day
Dirithromycin					500	mg
1ST GEN PENS
Penicillin G	2	million units/day	30	million units/day
	2000	units/kg/dy	400,000	units/kg/day
2ND GEN PENS
Cloxacillin	62.5	mg	500	mg
	12.5	mg/kg/day	100	mg/kg/day
Dicloxacillin	31.25	mg	500	mg
	3.125	mg/kg/day	100	mg/kg/day
Nafcillin	125	mg	2	g
	2.5	mg/kg	25	mg/kg
Oxacillin	62.5	mg	2	g
	125	mg	1000	mg
	25	mg/kg/day	200	mg/kg/day
	12.5	mg/kg/day	100	mg/kg/day
3RD GEN PENS
Amoxicillin	62.5	mg	875	mg
	5	mg/kg/day	45	mg/kg
Amoxicillin/clavulanic acid	62.5	mg	875	mg
	6.25	mg/kg/day	45	mg/kg/day
Ampicillin	62.5	mg	12	g/day q4
	6.25	mg/kg/day	300	mg/kg/day
Ampicillin/sulbactam	0.375	g	3	g	300	mg/kg/day
4TH GEN PENS
Mezlocillin	0.375	g	4	g	75	mg/kg
Piperacillin	1.5	g/day	24	g day
	25	mg/kg/day	300	mg/kg/day
Piperacillin/tazobactam			240	mg/kg/day
Ticarcillin	.25	g	4	g
	12.5	mg/kg/day	300	mg/kg/day
Ticarcillin/clavulanate	50	mg/kg/day	300	mg/kg/day
	0.775	g	3.1	g
1ST GEN QUINOLONES
Nalidixic Acid			55	mg/kg/day
2ND GEN QUINOLONES
Ciprofloxacin	50	mg	750	mg
	2.5	mg/kg/dose	15	mg/kg/dose
	62.5	mg	750	mg
	2.5	mg/kg/dose	15	mg/kg/dose
Enoxacin	50	mg	400	mg
Lomefloxacin			400	mg
Norfloxacin			400	mg
Ofloxacin	50	mg	400	mg
3RD GEN QUINOLONES
Levofloxacin	62.5	mg	750	mg
Sparfloxacin	50	mg	400	mg
4TH GEN QUINOLONES
Alatrofloxacin	50	mg	300	mg
Gatifloxacin	50	mg	400	mg
Moxifloxacin			400	mg
SULFAS
Trimethoprim/sulfamethoxazole	15	mg	800	mg
	3.75	mg/day	150	mg/day
Sulfisoxazole	18.75	mg	150	mg
Sulfamethoxazole	.25	g	2	g
TETRACYCLINES
Doxycycline	5	mg	100	mg
Minocycline	25	mg	200	mg
Tetracycline	62.5	mg	500	mg
OTHER
Chloramphenicol	12.5	mg/kg/day	100	mg/kg/day
Clindamycin	150	mg	900	mg
	37.5	mg	450	mg
	5	mg/kg/day	40	mg/kg/day
	2	mg/kg/day	25	mg/kg/day
Quinupristin/dalfopristin	1.875	mg/kg	7.5	mg/kg q8
Fosfomycin			3	g
Nitrofurantoin	12.5	mg	100	mg
	1.25	mg/kg/day	7	mg/kg/day
Rifampin	2.5	mg/kg	600	mg/kg
	2.5	mg/kg	600	mg/kg
Trimethoprim	25	mg	200	mg	10	mg/kg/day
Vancomycin					1	g
	2.5	mg/kg q6	15	mg/kg q8

[0120] In combating the infective diseases caused by gram-positive and gram-negative organisms, the compound of the formula I can be used in combination with other antibiotics that are active against gram-negative organisms. Examples of such gram-negative antibiotics are listed in Table 2. Some of gram-negative antibiotics may also have activity against gram-positive organisms.

TABLE 2
Gram-Negative Antibiotics That May Be Used
In a Combination Therapy with The Compound of Formula I
AGENTS	LO DOSE	HI DOSE	STD DOSE
AMINOGLYCOSIDES
Amikacin					15	mg/kg/day
Gentamicin	0.75	mg/kg/day	5	mg/kg/day
	0.5	mg/kg	2.5	mg/kg
Spectinomycin					40	mg/kg
Tobramycin	0.75	mg/kg/day	5	mg/kg/day
	0.5	mg/kg/day	5	mg/kg/day
PENEMS
Imipenem/cilastatin	62.5	mg	1	g
	6.25	mg/kg	25	mg/kg
Merpenem					40	mg/kg
	0.5	mg/kg	2.5	mg/kg
2ND GEN CEPHS
Cefaclor	62.5	mg	500	mg
	5	mg/kg/day	40	mg/kg/day
Cefotetan	0.125	g	3	g
	10	mg/kg/day	80	mg/kg/day
Cefoxitin	0.25	g	3	g
	20	mg/kg/day	160	mg/kg/day
Cefprozil	62.5	mg	500	mg
	1.875	mg/kg/dose	15	mg/kg/dose
Cefuroxime	187.5	mg	3	g
	31.25	mg	500	mg
	12.5	mg/kg/day	150	mg/kg/day
	31.25	mg/kg/day	500	mg/kg/day
Loracarbef	50	mg	400	mg
	3.75	mg/kg/day	500	mg/kg/day
3RD GEN CEPHS
Cefdinir	75	mg			600	mg qd
Cefixime	50	mg			400	mg
Cefoperazone	0.25	g/day	12	g/day
	25	mg/kg/day	150	mg/kg/day
Cefotaxime	0.25	g	2	g
	12.5	mg/kg/dose	300	mg/kg/day
Cefpodoxime	25	mg	400	mg	10	mg/kg/day
Ceftazidime	62.5	mg	2	g q8
	25	mg/kg/day	150	mg/kg/day
Ceftibuten	2.25	mg/kg	400	mg	400	mg
Ceftozoxime	0.25	g	4	g
	12.5	mg/kg/day	200	mg/kg/day
Ceftriaxone	31.25	mg	2	g
	12.5	mg/kg/day	100	mg/kg/day
4TH GEN CEPHS
Cefepime	0.125	g	2	g
	12.5	mg/kg	50	mg/kg q8
MACROLIDES
Azithromycin	62.5	mg	500	mg
	62.5	mg	500	mg
Clarithromycin	62.5	mg	500	mg	7.5	mg/kg/day
Dirithromycin					500	mg
3RD GEN PENS
Amoxicillin	62.5	mg	875	mg
	5	mg/kg/day	45	mg/kg
Amoxicillin/clavulanic acid	62.5	mg	875	mg
	6.25	mg/kg/day	45	mg/kg/day
Ampicillin	62.5	mg	12	g/day q4
	6.25	mg/kg/day	300	mg/kg/day
Ampicillin/sulbactam	0.375	g	3	g	300	mg/kg/day
4TH GEN PENS
Meziocillin	0.375	g	4	g	75	mg/kg
Piperacillin	1.5	g/day	24	g day
	25	mg/kg/day	300	mg/kg/day
Piperacillin/tazobactam					240	mg/kg/day
Ticarcillin	0.25	g	4	g
	12.5	mg/kg/day	300	mg/kg/day
Ticarcillin/clavulanate	50	mg/kg/day	300	mg/kg/day
	0.775	g	3.1	g
1ST GEN QUINOLONES
Nalidixic Acid					55	mg/kg/day
2ND GEN QUINOLONES
Ciprofloxacin	50	mg	750	mg
	2.5	mg/kg/dose	15	mg/kg/dose
	62.5	mg	750	mg
	2.5	mg/kg/dose	15	mg/kg/dose
Enoxacin	50	mg	400	mg
Lomefloxacin					400	mg
Norfloxacin					400	mg
Ofloxacin	50	mg	400	mg
3RD GEN QUINOLONES
Levofloxacin	62.5	mg	750	mg
Sparfloxacin	50	mg	400	mg
4TH GEN QUINOLONES
Alatrofloxacin	50	mg	300	mg
Gatifloxacin	50	mg	400	mg
Moxifloxacin					400	mg
SULFAS
Trimethoprim/sulfamethoxazole	15/200	mg
	3.75	mg/day	150	mg/day
Sulfisoxazole	18.75	mg	150	mg
Sulfamethoxazole	0.25	g	2	g
TETRACYCLINES
Doxycycline	5	mg	100	mg
Minocycline	25	mg	200	mg
Tetracycline	62.5	mg	500	mg
OTHER
Chloramphenicol	12.5	mg/kg/day	100	mg/kg/day
Aztreonam	125	mg	2	g
	37.5	mg	450	mg
	5	mg/kg/day	40	mg/kg/day
	2	mg/kg/day	25	mg/kg/day
Fosfomycin					3	g
Nitrofurantoin	12.5	mg	100	mg
	1.25	mg/kg/day	7	mg/kg/day
	2.5	mg/kg	600	mg/kg
Trimethoprim	25	mg	200	mg	10	mg/kg/day

[0121] In Tables 1 and 2, the term “Lo Dose” means the recommended lower dosage for the combination therapy of the invention. It may be adjusted even lower depending on the requirements of each subject being treated and the severity of the bacterial infection. The lowest dosage possible may be 0.1 mg when combined with the compound of formula I of the present invention. The term “Hi Dose” means the recommended highest dosage in the combination therapy. It may be changed hereafter according to the US FDA standard. The term “Std Dose” means the recommended standard dosage for the combination therapy of the present invention. It may be adjusted even lower depending on the requirements of each subject being treated and the severity of the bacterial infection. A specific antibiotic may have more than one the recommended dosage ranges.

[0122] Generally, an antibacterially effective amount of dosage of the compound of formula I of the present invention, either administered individually or in combination with other antibiotics, will be in the range of about 0.1 to about 400 mg/kg of body weight/day, more preferably about 1.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages of active component(s) may vary depending upon the requirements of each subject being treated and the severity of the bacterial infection. In average, the effective amount of an active component is about 20 mg to 800 mg and preferable is about 200 mg to 600 mg per day.

[0123] The desired dose may conveniently be presented in a single dose or as divided into multiple doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

[0124] Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired plasma concentration. On the other hand, the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation.

[0125] In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures know in the art may be used to determine the desired dosage amount.

[0126] For the combination therapy, the compound of formula I may be administered concurrently or concomitantly with other antibiotics. The term “concurrently” means the subject being treated takes one drug within about 5 minutes of taking the other drug. The term “concomitantly” means the subject being treated takes one drug within the same treatment period of taking the other drug. The same treatment period is preferably within twelve hours and up to forty-eight hours.

[0127] For the combination therapy, the compound of formula I, and one or more other antibiotics may be administered in the same physical form or separately, i.e., they may be administered in the same delivery vehicle or in different delivery vehicles.

[0128] For the combination therapy, some of the antibiotics may further be used with a β-Lactamase inhibitor. For example, Imipenem may be used with cilastatin, Ampicillin may be used with sulbactam, Piperacillin may be used with tazobactam, and Ampicillin may be used with sulbactam.

[0129] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Amikacin.

[0130] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Gentamicin.

[0131] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Spectinomycin.

[0132] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Tobramycin.

[0133] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Imipenem/cilastatin.

[0134] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Meropenem.

[0135] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefadroxil.

[0136] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefazolin.

[0137] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cephalexin.

[0138] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefaclor.

[0139] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefotetan.

[0140] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefoxitin.

[0141] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefprozil.

[0142] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefuroxime.

[0143] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Loracarbef

[0144] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefdinir.

[0145] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefixime.

[0146] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefoperazone.

[0147] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefotaxime.

[0148] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefpodoxime.

[0149] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ceftazidime.

[0150] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ceftibuten.

[0151] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ceftozoxime.

[0152] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ceftriaxone.

[0153] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cefepime.

[0154] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Azithromycin.

[0155] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Clarithromycin.

[0156] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Dirithromycin.

[0157] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Penicillin G.

[0158] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Cloxacillin.

[0159] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Dicloxacillin.

[0160] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Nafcillin.

[0161] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Oxacillin.

[0162] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Amoxicillin.

[0163] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Amoxicillin/clavulanic acid.

[0164] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ampicillin.

[0165] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ampicillin/sulbactam.

[0166] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Mezlocillin.

[0167] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Piperacillin.

[0168] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Piperacillin/tazobactam.

[0169] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ticarcillin.

[0170] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ticarcillin/clavulanate.

[0171] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Nalidixic Acid.

[0172] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ciprofloxacin.

[0173] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Enoxacin.

[0174] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Lomefloxacin.

[0175] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Norfloxacin.

[0176] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Ofioxacin.

[0177] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Levofloxacin.

[0178] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Sparfloxacin.

[0179] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Alatrofloxacin.

[0180] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Gatifloxacin.

[0181] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Moxifloxacin.

[0182] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Trimethoprim/sulfamethoxazole.

[0183] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Sulfisoxazole.

[0184] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Sulfamethoxazole.

[0185] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Doxycycline.

[0186] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Minocycline.

[0187] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Tetracycline.

[0188] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Aztreonam.

[0189] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Chloramphenicol.

[0190] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Clindamycin.

[0191] Specifically, the combination therapy of the present-invention is the compound of formula I of the present invention with Quinupristin/dalfopristin.

[0192] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Fosfomycin.

[0193] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Metronidazole.

[0194] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Nitrofurantoin.

[0195] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Rifanpin.

[0196] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Trimethoprim.

[0197] Specifically, the combination therapy of the present invention is the compound of formula I of the present invention with Vancomycin.

[0198] Routes of Administration

[0199] In therapeutic use for treating, or combating, bacterial infections in a mammal (i.e. human and animals) a compound of the present invention, its pharmaceutical compositions, or combining with other antibacterial agents can be administered orally, parenterally, topically, rectally, transmucosally, or intestinally.

[0200] Parenteral administrations include indirect injections to generate a systemic effect or direct injections to the afflicted area. Examples of parenteral administrations are subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular, intranasal, intravetricular injections or infuisions techniques.

[0201] Topical administrations include the treatment of infectious areas or organs readily accessibly by local application, such as, for example, eyes, ears including external and middle ear infections, vaginal, open wound, skins including the surface skin and the underneath dermal structures, or other lower intestinal tract. Topical administrations also include transdermal delivery to generate a systemic effect.

[0202] The rectal administration includes the form of suppositories.

[0203] The transmucosal administration includes nasal aerosol or inhalation applications.

[0204] The preferred routes of administration are oral and parenteral.

[0205] Corposition/Formulation

[0206] Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulation, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.

[0207] Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0208] For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, solutions, emulsions, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. A carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Examples of such carriers or excipients include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, sucrose, pectin, dextrin, mnnitol, sorbitol, starches, gelatin, cellulosic materials, low melting wax, cocoa butter or powder, polymers such as polyethylene glycols and other pharmaceutical acceptable materials.

[0209] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identificatin or to characterize different combinations of active compound doses.

[0210] Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, liquid polyethylene glycols, cremophor, capmul, medium or long chain mono-, fi- or triglycerides. Stabilizers may be added in these formulations, also.

[0211] Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

[0212] The compounds may also be formulated for parenteral administration, e.g., by injections, bolus injection or continuous infusion. Formulations for parenteral administration may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating materials such as suspending, stabilizing and/or dispersing agents.

[0213] For injection, the compounds of the invention may be formulated in aqueous solution, preferably in physiologically compatible buffers or physiological saline buffer. Suitable buffering agents include trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine.

[0214] Parenteral administrations also include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0215] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.

[0216] For suppository administration, the compounds may also be formulated by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and other glycerides.

[0217] For administration by inhalation, compounds of the present invention can be conveniently delivered through an aerosol spray in the form of solution, dry powder, or suspensions. The aerosol may use a pressurized pack or a nebulizer and a suitable propellant. In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler may be formulated containing a power base such as lactose or starch.

[0218] For topical applications, the pharmaceutical composition may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Aternatively, the pharmaceutical compositions can be formulated in a suitable lotion such as suspensions, emulsion, or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, ceteary alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0219] For ophthalmic and otitis uses, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

[0220] In addition to the formulations described previously, the compounds may also be formulated as depot preparations. Such long acting formulations may be in the forms of implants. A compound of this invention may be formulated for this route of administration with suitable biopolymers, hydrophbic materials, or as a sparing soluble derivative such as, without limitation, a sparingly soluble salt.

[0221] Additionally, the compounds may be delivered using a sustained-release system. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for 24 hours up to several days. Depending on the chemical natrue and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

[0222] The quantity of active component, that is the compound this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the manner of administration, the potency of the particular compound and the desired concentration. Determination of a therapeutically effective amount is well within the capability of those skilled in the art. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.

Claims

1. A compound of formula I

2. A compound of claim 1 wherein R2 and R3 are H.

3. A compound of claim 1 wherein R2 and R3 are F.

4. A compound of claim 1 wherein R2 is H and R3 is F.

5. A compound of claim 2 wherein R1 is H.

6. A compound of claim 3 wherein R1 is H.

7. A compound of claim 4 wherein R1 is H.

8. A compound of claim 5, 6, or 7 wherein X is N.

9. A compound of claim 5, 6, or 7 wherein X is CH.

10. A compound of claim 1 which is (a) 2,2-Difluoro-N-({(5S)-3-[3,5-difluoro-4-(4-glycoloyl-piperazine-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide, (b) 2-{4-[4-((5S)-5-{[(2,2-difluoroethanethiolyl)-amino]methyl}-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]piperazin-1-yl}-2-oxoethyl Acetate, (c) 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(4-glycoloylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioaamide, (d) 2,2-difluoro-N-({(5S)-3-[4-glycoloylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-ethanethioamide, or (e) N-{[(5S)-3-(4-{4-[(benzyloxy)acetyl]piperazin-1-yl}phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-2,2-difluoroethanethioamide.

11. A compound of claim 1 which is 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(4-glycoloylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide.

12. A compound of claim 1 which is (a) 2,2-difluoro-N-({(5S)-3-[3-fluoro-4-(1-glycoloylpiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide, or (b) 2,2-difluoro-N-({(5S)-3-[4-(1-glycoloylpiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide.

13. A compound of formula Ia useful as a intermediate for the preparation of a compound of formula I

14. A method for treating bacteria infections comprising administering to a mammal being treated a pharmaceutically effective amount of the compound of claim 1.

15. The method of claim 14 wherein the compound of claim 1 is administered parenterally, topically, rectally, or intranasally.

16. The method of claim 14 wherein the compound of claim 1 is administered orally.

17. The method of claim 15 wherein parenteral administration is subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular, intravetricular injection.

18. The method of claim 15 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

19. The method of claim 15 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

20. The method of claim 14 wherein said infection is skin infection.

21. The method of claim 14 wherein the infection is eye infection.

22. The method of claim 14 wherein the infection is ear infection.

23. The method of claim 14 wherein said mammal is human.

24. The method of claim 14 wherein said mammal is an animal.

25. A pharmaceutical composition comprising the compound of claim 1 or its pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.

26. A method for treating bacteria infections in a mammal comprising administering to said mammal (a) a pharmaceutically effective amount of the compound of claim 1 or a pharmaceutically effective salt thereof, and (b) a pharmaceutically effective amount of at least one antibiotic or a pharmaceutically effective salt thereof.

27. The method of claim 26 wherein the antibiotic is Amikacin, Gentamicin, Spectinomycin, Tobramycin, Imipenem, Meropenem, Cefadroxil, Cefazolin, Cephalexin, Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Loracarbef, Cefdinir, Cefixime, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftozoxime, Ceftriaxone, Cefepime, Azithromycin, Clarithromycin, Dirithromycin, Penicillin G, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Amoxicillin, Ampicillin, Mezlocillin, Piperacillin, Nalidixic Acid, Ciprofloxacin, Enoxacin, Lomefloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Sparfloxacin, Alatrofloxacin, Gatifloxacin, Moxifloxacin, Trimethoprim, Sulfisoxazole, Sulfamethoxazole, Doxycycline, Minocycline, Tetracycline, Aztreonam, Chloramphenicol, Clindamycin, Quinupristin, Fosfomycin, Metronidazole, Nitrofurantoin, Rifampin, Trimethoprim, or Vancomycin.

28. A method for treating bacteria infections caused by gram-positive bacteria in a mammal comprising administering to said mammal (a) a pharmaceutically effective amount of compound of the formula I as shown in claim 1 or a pharmaceutically effective salt thereof, and (b) a pharmaceutically effective amount of at least one antibiotic or a pharmaceutically effective salt thereof.

29. The method of claim 28 wherein the antibiotic is Amikacin, Gentamicin, Spectinomycin, Tobramycin, Imipenem, Meropenem, Cefadroxil, Cefazolin, Cephalexin, Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Loracarbef, Cefdinir, Cefixime, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftozoxime, Ceftriaxone, Cefepime, Azithromycin, Clarithromycin, Dirithromycin, Penicillin G, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Amoxicillin, Ampicillin, Mezlocillin, Piperacillin, Nalidixic Acid, Ciprofloxacin, Enoxacin, Lomefloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Sparfloxacin, Alatrofloxacin, Gatifloxacin, Moxifloxacin, Trimethoprim, Sulfisoxazole, Sulfamethoxazole, Doxycycline, Minocycline, Tetracycline, Chloramphenicol, Clindamycin, Quinupristin/dalfopristin, Fosfomycin, Nitrofurantoin, Rifampin, Trimethoprim, or Vancomycin.

30. A method for treating bacteria infections caused by gram-negative bacteria in a mammal comprising administering to said mammal (a) a pharmaceutically effective amount of the compound of claim 1 or a pharmaceutically effective salt thereof, and (b) a pharmaceutically effective amount of one or more antibiotics or a pharmaceutically effective salt thereof.

31. The method of claim 30 wherein the antibiotic is Amikacin, Gentamicin, Spectinomycin, Tobramycin, Imipenem, Meropenem, Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Loracarbef, Cefdinir, Cefixime, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftozoxime, Ceftriaxone, Cefepime, Azithromycin, Clarithromycin, Dirithromycin, Amoxicillin, Amoxicillin, Ampicillin, Ampicillin, Mezlocillin, Piperacillin, Piperacillin, Nalidixic Acid, Ciprofloxacin, Enoxacin, Lomefloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Sparfloxacin, Alatrofloxacin, Gatifloxacin, Moxifloxacin, Trimethoprim, Sulfisoxazole, Sulfamethoxazole, Doxycycline, Minocycline, Tetracycline, Aztreonam, Chloramphenicol, Fosfomycin, Nitrofurantoin, or Trimethoprim.

32. The method of claims 26 wherein the compound of formula I and the other antibiotic are administered parenterally, topically, rectally, or intranasally.

33. The method of claims 26 wherein the compound of formula I and the other antibiotic are administered orally.

34. The method of claim 32 wherein parenteral administration is subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular, intravetricular injection.

35. The method of claims 26 wherein said infection is skin infection.

36. The method of claims 26 wherein said mammal is human.

37. The method of claims 26 wherein said mammal is an animal.

38. The method of claims 26 wherein the compound of formula I and the antibiotic are concomitantly administered.

39. The method of claims 26 wherein the compound of formula I and the antibiotics are concurrently administered.

40. A composition comprising: (a) a pharmaceutically effective amount of the compound of formula I as shown in claim 1 or a pharmaceutically effective salt thereof, (b) a pharmaceutically effective amount of one or more antibiotics or a pharmaceutically effective salt thereof, and (c) a pharmaceutically acceptable carrier.

41. The composition of claim 40 wherein the antibiotic is Amikacin, Gentamicin, Spectinomycin, Tobramycin, Imipenem, Meropenem, Cefadroxil, Cefazolin, Cephalexin, Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Loracarbef, Cefdinir, Cefixime, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftozoxime, Ceftriaxone, Cefepime, Azithromycin, Clarithromycin, Dirithromycin, Penicillin G, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Amoxicillin, Ampicillin, Mezlocillin, Piperacillin, Nalidixic Acid, Ciprofloxacin, Enoxacin, Lomefloxacin, Norfloxacin, Ofloxacin, Levofloxacin, Sparfloxacin, Alatrofloxacin, Gatifloxacin, Moxifloxacin, Trimethoprirm, Sulfisoxazole, Sulfamethoxazole, Doxycycline, Minocycline, Tetracycline, Aztreonam, Chloramphenicol, Clindamycin, Quinupristin, Fosfomycin, Metronidazole, Nitrofurantoin, Rifampin, Trimethoprim, and Vancomycin.